- Current report filing (8-K)
February 02 2009 - 7:00AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported):
January 27, 2009
SUNESIS
PHARMACEUTICALS, INC.
|
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
|
(State
or other jurisdiction
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
of
incorporation)
|
|
|
|
|
|
|
|
|
|
|
395 Oyster Point Boulevard, Suite 400
South
San Francisco, California
|
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
Registrant’s
telephone number, including area code:
(650)
266-3500
|
|
|
(Former
name or former address, if changed since last
report.)
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.02. Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On
January 27, 2009,
Jonathan S. Leff notified
the Board of Directors
of Sunesis Pharmaceuticals, Inc. ("Sunesis") of
his resignation as a director, effective February 3, 2009. Mr. Leff’s
resignation was not the result of any disagreement with Sunesis on any matter
relating to its operations, policies or practices, or regarding the general
direction of Sunesis.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Dated: February
2, 2009
|
SUNESIS
PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/ Valerie L. Pierce
|
|
Valerie
L. Pierce
|
|
Senior
Vice President, General Counsel and Corporate
Secretary
|
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Sunesis Pharmaceuticals Inc (NASDAQ): 0 recent articles
More News Articles